The role of iron and copper in the aetiology of neurodegenerative disorders

Therapeutic implications

George Perry, Lawrence M. Sayre, Craig S. Atwood, Rudolph J. Castellani, Adam D. Cash, Catherine Rottkamp, Mark A. Smith

Research output: Contribution to journalReview article

120 Citations (Scopus)

Abstract

Abnormalities in the metabolism of the transition metals iron and copper have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed in this article in depth. While there is documented evidence for alterations in the homeostasis, redox-activity and localisation of transition metals, it is also important to realise that alterations in specific copper- and iron-containing metalloenzymes appear to play a crucial role in the neurodegenerative process. These changes provide the opportunity to identify pathways where modification of the disease process can occur, potentially offering opportunities for clinical intervention. As understanding of disease aetiology evolves, so do the tools with which diseases are treated. In this article, we examine not only the possible mechanism of disease but also how pharmaceuticals may intervene, from direct and indirect antioxidant therapy to strategies involving gene therapy.

Original languageEnglish (US)
Pages (from-to)339-352
Number of pages14
JournalCNS Drugs
Volume16
Issue number5
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Neurodegenerative Diseases
Copper
Iron
Metals
Homeostasis
Therapeutics
Genetic Therapy
Oxidation-Reduction
Antioxidants
Brain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Perry, G., Sayre, L. M., Atwood, C. S., Castellani, R. J., Cash, A. D., Rottkamp, C., & Smith, M. A. (2002). The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications. CNS Drugs, 16(5), 339-352. https://doi.org/10.2165/00023210-200216050-00006

The role of iron and copper in the aetiology of neurodegenerative disorders : Therapeutic implications. / Perry, George; Sayre, Lawrence M.; Atwood, Craig S.; Castellani, Rudolph J.; Cash, Adam D.; Rottkamp, Catherine; Smith, Mark A.

In: CNS Drugs, Vol. 16, No. 5, 01.01.2002, p. 339-352.

Research output: Contribution to journalReview article

Perry, George ; Sayre, Lawrence M. ; Atwood, Craig S. ; Castellani, Rudolph J. ; Cash, Adam D. ; Rottkamp, Catherine ; Smith, Mark A. / The role of iron and copper in the aetiology of neurodegenerative disorders : Therapeutic implications. In: CNS Drugs. 2002 ; Vol. 16, No. 5. pp. 339-352.
@article{f9fd48ff9632475788f581b8d2bf3422,
title = "The role of iron and copper in the aetiology of neurodegenerative disorders: Therapeutic implications",
abstract = "Abnormalities in the metabolism of the transition metals iron and copper have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed in this article in depth. While there is documented evidence for alterations in the homeostasis, redox-activity and localisation of transition metals, it is also important to realise that alterations in specific copper- and iron-containing metalloenzymes appear to play a crucial role in the neurodegenerative process. These changes provide the opportunity to identify pathways where modification of the disease process can occur, potentially offering opportunities for clinical intervention. As understanding of disease aetiology evolves, so do the tools with which diseases are treated. In this article, we examine not only the possible mechanism of disease but also how pharmaceuticals may intervene, from direct and indirect antioxidant therapy to strategies involving gene therapy.",
author = "George Perry and Sayre, {Lawrence M.} and Atwood, {Craig S.} and Castellani, {Rudolph J.} and Cash, {Adam D.} and Catherine Rottkamp and Smith, {Mark A.}",
year = "2002",
month = "1",
day = "1",
doi = "10.2165/00023210-200216050-00006",
language = "English (US)",
volume = "16",
pages = "339--352",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - The role of iron and copper in the aetiology of neurodegenerative disorders

T2 - Therapeutic implications

AU - Perry, George

AU - Sayre, Lawrence M.

AU - Atwood, Craig S.

AU - Castellani, Rudolph J.

AU - Cash, Adam D.

AU - Rottkamp, Catherine

AU - Smith, Mark A.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Abnormalities in the metabolism of the transition metals iron and copper have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed in this article in depth. While there is documented evidence for alterations in the homeostasis, redox-activity and localisation of transition metals, it is also important to realise that alterations in specific copper- and iron-containing metalloenzymes appear to play a crucial role in the neurodegenerative process. These changes provide the opportunity to identify pathways where modification of the disease process can occur, potentially offering opportunities for clinical intervention. As understanding of disease aetiology evolves, so do the tools with which diseases are treated. In this article, we examine not only the possible mechanism of disease but also how pharmaceuticals may intervene, from direct and indirect antioxidant therapy to strategies involving gene therapy.

AB - Abnormalities in the metabolism of the transition metals iron and copper have been demonstrated to play a crucial role in the pathogenesis of various neurodegenerative diseases. Metal homeostasis as it pertains to alterations in brain function in neurodegenerative diseases is reviewed in this article in depth. While there is documented evidence for alterations in the homeostasis, redox-activity and localisation of transition metals, it is also important to realise that alterations in specific copper- and iron-containing metalloenzymes appear to play a crucial role in the neurodegenerative process. These changes provide the opportunity to identify pathways where modification of the disease process can occur, potentially offering opportunities for clinical intervention. As understanding of disease aetiology evolves, so do the tools with which diseases are treated. In this article, we examine not only the possible mechanism of disease but also how pharmaceuticals may intervene, from direct and indirect antioxidant therapy to strategies involving gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=0036113819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036113819&partnerID=8YFLogxK

U2 - 10.2165/00023210-200216050-00006

DO - 10.2165/00023210-200216050-00006

M3 - Review article

VL - 16

SP - 339

EP - 352

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 5

ER -